Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

1,630 public trials 214 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +90 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 21 locations
View Trial Details
Recruiting

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

NCT06854653

Conditions
CTCL, Disease Attributes, Hemic and Lymphatic Diseases, +15 more
Locations
  • City of Hope Comprehensive Cancer Cente Duarte, California, United States
  • University of California Irvine Irvine, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 15 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078

Conditions
Disease Attributes, Hematologic Diseases, Hematologic Neoplasms, +17 more
Locations
  • St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Providence St. John's Health Center Santa Monica, California, United States
View all 45 locations
View Trial Details
Recruiting

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

NCT05998642

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Arthur J.E. Child Comprehensive Cancer Centre Calgary, Alberta, Canada
  • BCCA - Vancouver Vancouver, British Columbia, Canada
  • Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada
  • Ottawa Hospital Research Institute Ottawa, Ontario, Canada
View Trial Details
Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265

Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
Locations
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
View Trial Details

Related conditions